Company: DNLI
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001714899-25-000067
Chunk: 2

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 8-K
Item: Item 1.02
Chunk 2
---
Item 1.02 Termination of a Material Definitive Agreement

On February 27, 2025, the Company terminated its equity distribution agreement, dated February 28, 2022, by and between the Company, Goldman Sachs & Co. LLC (“ Goldman”), Leerink Partners LLC (“ Leerink Partners”), and Cantor Fitzgerald & Co. ("Cantor") (the “ Prior Sales Agreement”), pursuant to which the Company was permitted to sell shares of common stock in “at-the-market offerings” as defined by Rule 415 of the Securities Act. The Company previously filed a prospectus, dated February 28, 2022, relating to the at-the-market offering of shares of common stock pursuant to the Prior Sales Agreement (the “ ATM Prospectus”). The offering pursuant to the ATM Prospectus was terminated in connection with the termination of the Prior Sales Agreement. Following such termination, the Company may not offer or sell any additional shares of its common stock under the Prior Sales Agreement and ATM Prospectus.

Item 2.02 Results of Operations and Financial Condition.